Yayun Gu1,2, Cheng Wang1,2,3, Rongxuan Zhu4, Jianshui Yang1, Wenwen Yuan1,2, Yanhui Zhu5, Yan Zhou1,2, Na Qin1,2, Hongbing Shen1,2, Hongxia Ma1,2, Hongxia Wang4, Xiaoan Liu5, Zhibin Hu1,2. 1. State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China. 2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211116, China. 3. Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. 4. Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China. 5. Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Abstract
Objective: The newly defined cancer-testis (CT) gene, MEIOB, was previously found to play key roles in DNA double-strand break (DSB) repair. In this study, we aimed to investigate the effects and mechanisms of MEIOB in the carcinogenesis of triple-negative breast cancers (TNBCs). Methods: The Cancer Genome Atlas database was used to quantify the expression of MEIOB. Cox regression analysis was used to evaluate the association between MEIOB expression and the prognosis of human TNBC. The effects of MEIOB on cell proliferation and migration in TNBCs were also assessed in vitro. Patient-derived xenograft (PDX) models were used to assess the sensitivity of breast cancers with active MEIOB to PARP1 inhibitors. Results: We confirmed MEIOB as a CT gene whose expression was restricted to the testes and breast tumors, especially TNBCs. Its activation was significantly associated with poor survival in breast cancer patients [overall, hazard ratio (HR) = 1.90 (1.16-2.06); TNBCs: HR = 7.05 (1.16-41.80)]. In addition, we found that MEIOB was oncogenic and significantly promoted the proliferation of TNBC cells. Further analysis showed that MEIOB participated in DSB repair in TNBCs. However, in contrast to its function in meiosis, it mediated homologous recombination deficiency (HRD) through the activation of polyADP-ribose polymerase (PARP)1 by interacting with YBX1. Furthermore, activated MEIOB was shown to confer sensitivity to PARP inhibitors, which was confirmed in PDX models. Conclusions: MEIOB played an oncogenic role in TNBC through its involvement in HRD. In addition, dysregulation of MEIOB sensitized TNBC cells to PARP inhibitors, so MEIOB may be a therapeutic target of PARP1 inhibitors in TNBC. Copyright:
Objective: The newly defined cancer-testis (CT) gene, MEIOB, was previously found to play key roles in DNA double-strand break (DSB) repair. In this study, we aimed to investigate the effects and mechanisms of MEIOB in the carcinogenesis of triple-negative breast cancers (TNBCs). Methods: The Cancer Genome Atlas database was used to quantify the expression of MEIOB. Cox regression analysis was used to evaluate the association between MEIOB expression and the prognosis of human TNBC. The effects of MEIOB on cell proliferation and migration in TNBCs were also assessed in vitro. Patient-derived xenograft (PDX) models were used to assess the sensitivity of breast cancers with active MEIOB to PARP1 inhibitors. Results: We confirmed MEIOB as a CT gene whose expression was restricted to the testes and breast tumors, especially TNBCs. Its activation was significantly associated with poor survival in breast cancer patients [overall, hazard ratio (HR) = 1.90 (1.16-2.06); TNBCs: HR = 7.05 (1.16-41.80)]. In addition, we found that MEIOB was oncogenic and significantly promoted the proliferation of TNBC cells. Further analysis showed that MEIOB participated in DSB repair in TNBCs. However, in contrast to its function in meiosis, it mediated homologous recombination deficiency (HRD) through the activation of polyADP-ribose polymerase (PARP)1 by interacting with YBX1. Furthermore, activated MEIOB was shown to confer sensitivity to PARP inhibitors, which was confirmed in PDX models. Conclusions: MEIOB played an oncogenic role in TNBC through its involvement in HRD. In addition, dysregulation of MEIOB sensitized TNBC cells to PARP inhibitors, so MEIOB may be a therapeutic target of PARP1 inhibitors in TNBC. Copyright:
Authors: Simon Anders; Davis J McCarthy; Yunshun Chen; Michal Okoniewski; Gordon K Smyth; Wolfgang Huber; Mark D Robinson Journal: Nat Protoc Date: 2013-08-22 Impact factor: 13.491
Authors: Jenny G Parvani; Maneesh D Gujrati; Margaret A Mack; William P Schiemann; Zheng-Rong Lu Journal: Cancer Res Date: 2015-04-09 Impact factor: 12.701
Authors: Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl Journal: Lancet Oncol Date: 2017-12-07 Impact factor: 41.316
Authors: Judy C Boughey; Karla V Ballman; Linda M McCall; Elizabeth A Mittendorf; William Fraser Symmans; Thomas B Julian; David Byrd; Kelly K Hunt Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: J H Park; S F Jonas; G Bataillon; C Criscitiello; R Salgado; S Loi; G Viale; H J Lee; M V Dieci; S-B Kim; A Vincent-Salomon; G Curigliano; F André; S Michiels Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Elizaveta E Alemasova; Nina A Moor; Konstantin N Naumenko; Mikhail M Kutuzov; Maria V Sukhanova; Pavel E Pestryakov; Olga I Lavrik Journal: Biochim Biophys Acta Date: 2016-08-18
Authors: Raphael Ceccaldi; Jessica C Liu; Ravindra Amunugama; Ildiko Hajdu; Benjamin Primack; Mark I R Petalcorin; Kevin W O'Connor; Panagiotis A Konstantinopoulos; Stephen J Elledge; Simon J Boulton; Timur Yusufzai; Alan D D'Andrea Journal: Nature Date: 2015-02-02 Impact factor: 69.504